AMG 133 is a bispecific molecule that addresses two targets, GLP-1 and GIPR, and in a phase 1 study achieved clinically significant body weight reductions over 12 weeks in people with obesity and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback